SCHEMBL6908092

SCHEMBL6908092

[Al]Oc1ccc2ccccc2c1-c1cccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DNMT1 P26358 1/20 0.42
TYMP P19971 1/20 0.41
HSD17B10 Q99714 2/20 0.39
CYP2A6 P11509 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
DHFR P00374 1/20 0.39
PTPN1 P18031 1/20 0.39
GSK3B P49841 1/20 0.38
ADK P55263 1/20 0.38
SLC22A12 Q96S37 1/20 0.37
HPRT1 P00492 1/20 0.37
NSD2 O96028 1/20 0.36
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29512056 0.81 MAPT (0.75) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL12880138 0.81 MAPT (0.75) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL7954034 0.81 MAPT (0.48) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL6287732 0.81 MAPT (0.48) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL9874312 0.81 MAPT (0.48) MAPTALDH1A1MEN1KMT2ARAB9A
Bromide SCHEMBL7960862 0.80 MAPT (0.47) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL9874308 0.80 MAPT (0.47) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL23581815 0.77 MAPT (0.44) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL14232481 0.77 MAPT (0.54) MAPTALDH1A1MEN1KMT2ARAB9A
SCHEMBL12223406 0.77 ALOX5 (0.57) MAPTALDH1A1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730626-B2 TRANSITION METAL DERIVATIVE CAN REACT TO FORM AN IONIC COMPLEX WITH THE ALUMINOXANE IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2004-05-04 US disclosed
EP-1323723-A1 TRANSITION METAL COMPOUNDS, POLYMERIZATION CATALYSTS FOR OLEFINS, OLEFIN POLYMERS AND PROCESS FOR THEIR PRODUCTION IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2003-07-02 EP disclosed
US-20020193536-A1 Transition metal compound, polymerization catalysts for olefins, olefin polymers and process for their production IDEMITSU KOSAN CO. LTD. (JP) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193536-A1 Transition metal compound, polymerization catalysts for olefins, olefin polymers and process for their production CCNE2, PYM1, AP1M1 MAPT 2296/4885ALDH1A1 2755/4885MEN1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.